2026-526102-33-00
Recruiting
Phase 4
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
Laboratorios Cinfa S.A.1 site in 1 country32 target enrollmentStarted: May 11, 2026Last updated:
ConditionsNo medical condition
Overview
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Laboratorios Cinfa S.A.
- Enrollment
- 32
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Rubén Rubén Estepa Sanz
Scientific
Laboratorios Cinfa S.A.
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.2025-521732-11-00Laboratorios Cinfa S.A.32
Completed
Phase 1
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 12 mg film-coated tablets versus reference product Fycompa 12 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.2023-503345-59-00Laboratorios Cinfa S.A.36
Not yet recruiting
Phase 1
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.2025-524035-39-00Laboratorios Cinfa S.A.32
Completed
Phase 1
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 2 mg film-coated tablets versus reference product Fycompa 2 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions.2023-504132-18-00Laboratorios Cinfa S.A.36
Completed
Phase 1
An open label, randomized, single-dose, two-sequence, two-period, crossover comparative bioavailability study to assess the pharmacokinetic and safety profile of Dofetilide intravenous solution compared to Tikosyn® (Dofetilide) oral capsule in healthy subjects under fasting conditions.2023-510176-31-00Hyloris Developments20